IPSEY
Ipsen
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Ipsen completed its acquisition of Kartos Therapeutics, strengthening its late-stage oncology pipelineAug 21, 2026
- Dysport became the first botulinum toxin to achieve positive Phase 3 topline results in both episodic and chronic migraineJul 9, 2026
- Ipsen agreed to acquire Memo Therapeutics, expanding its rare disease portfolioJul 1, 2026
- New data further supports IQIRVO benefits on ALP, fatigue and itching in PBC patientsMay 28, 2026
- Ojemda was approved in the European Union as the first targeted therapy for relapsed or refractory pediatric low-grade glioma regardless of BRAF statusApr 22, 2026